To assess the cost and effectiveness of risperidone, olanzapine, and conventional antipsychotic medications under "usual practice" conditions in a large, public mental health system, 108 persons diagnosed with schizophrenia or schizoaffective disorder were randomly assigned to one of these three medication groups and followed prospectively over a 12-month period using standard instruments and procedures. Psychiatric medication costs increased more over time in both the olanzapine and risperidone groups than in the conventional medication group. Compliance with the prescribed medication was higher in the olanzapine group than in the conventional group. No differential effects by medication group were evident in this sample on the symptoms of schizophrenia, side effects, psychosocial functioning, time to discharge for index hospitalization, survival to initial rehospitalizatlon, or client satisfaction with services. These results extend findings from previous efficacy and naturalistic studies in several ways but are limited chiefly by the small number of subjects who completed 6 to 12 months of the clinical trial, and the resulting power to detect differences in the statistical analyses.
During the past decade, there has been unprecedented development of "novel" antipsychotic medications that display many promising outcomes in efficacy studies. Both risperidone and olanzapine have been shown to be more effective than conventional antipsychotic medications in treating positive psychotic symptoms in short-term (4-6 week) clinical trials, but the results are not always consistent across studies (Marder and Meibach 1994; Peuskens 1995; Beasley etal. 1996a Beasley etal. , 19966, 1997 Leucht et al. 1999) . The improvement in negative symptoms by the novel medications is modestly superior to the improvement seen with conventional antipsychotic medications (Marder and Meibach 1994; Peuskens 1995; Beasley et al. 1996a; Tollefson et al. 1997; Leucht et al. 1999) . Similarly, the improvement in some dimensions of general psychopathology with the use of novel medications is also modestly superior to that seen with conventional antipsychotic medications (Marder and Meibach 1994; Lindstrom et al. 1995; Fulton and Goa 1997; Tollefson et al. 1997; Leucht etal. 1999) .
Only three studies have been published to date comparing these newer medications with each other Ho et al. 1999; Conley and Mahmoud 2001) , and the limitations of one of these studies have been discussed in the literature (Gheuens and Grebb 1998; Kasper and Kufferle 1998; Schooler 1998) . In one randomized clinical trial (RCT) study, olanzapine was more effective than risperidone with regard to improvement in negative symptoms and general psychopathology, and more of those treated with olanzapine maintained their improvement in positive and negative symptoms during the 28-week trial . Mood symptoms, especially depression, improved more in patients treated with olanzapine compared with risperidone in an 8-week period, but there was no significant difference in improvement in mood symptoms between the two novel medications at 28 weeks ). The nonrandomized comparative study found that, although both medications effectively relieved positive and negative symptoms by the end of the index hospitalization (about 4 weeks), risperidone was more effective in reducing positive symptoms over the next 6 months of maintenance treatment (Ho et al. 1999) . Risperidone was associated with more extrapyramidal symptoms (EPS) than olanzapine ) and with more akathisia and use of anticholinergic medications during and at discharge from the index inpatient episode, but there were no differences at 6-month followup (Ho et al. 1999) .
The most recent study comparing the safety and efficacy of olanzapine and risperidone in a double-blind RCT found no differences between the groups in terms of completing the trial, or the reporting or severity of EPS, but at week 8 improvements on the Positive and Negative Syndrome Scale (PANSS) factor scores for positive symptoms and anxiety/depression were greater for risperidone, and there was more weight gain in the olanzapine group (Conley and Mahmoud 2001) .
During the same period of time, there have been many calls-from various clinical management, pharmacoeconomic, and public policy perspectives-for additional comparative studies of the newer and older medications, using a broad array of outcome measures (i.e., psychosocial functioning, medication compliance, drug and alcohol use, service utilization, including rehospitalization, and costs of care) and conducted in public sector settings (Hargreaves and Shumway 1996; Lehman 1996 ; Collaborative Working Group on Clinical Trial Evaluations 1998; DeQuardo and Tandon 1998; Revicki 1999; Tunis et al. 1999; Wells 1999) . Such studies would allow cost-effectiveness results to be used in clinical management and public policy decision making. Two of the comparative investigations to date have incorporated quality of life as an outcome measure, yielding results at 6-month followup of no significant difference between olanzapine and risperidone (Ho et al. 1999 ) on this measure; whereas, the olanzapine group demonstrated significantly greater improvement in interpersonal relations over the 28 weeks of followup . However, no other study has been conducted in a usual practice, public mental health treatment system. The present study addresses this need for comparative results from public mental health systems, having emerged from lobbying efforts directed toward state authorities by pharmaceutical companies anticipating greatly reduced hospitalization costs with increased use of novel medications. The primary aim of this study was to assess and compare the effectiveness and costs of two novel antipsychotic medications with traditional antipsychotic medications among patients diagnosed with schizophrenia or schizoaffective disorder who had two or more recent acute hospitalizations and who were noncompliant with their pharmacotherapy interventions or otherwise unstable in their maintenance treatment. A variety of efficacy and effectiveness measures were employed so that results would be not only useful to public officials but also comparable to extant data from prior efficacy and naturalistic studies. The working hypothesis in this study was that outcomes on a variety of dimensions would be better for those receiving novel medications but that care costs would be higher in these two groups as well.
Methods
Research Site Description. The public mental health system of this small southeastern state, which includes 17 local mental health centers and two acute psychiatric facilities, is operated directly by the state department of mental health (DMH). About 51,000 unduplicated adult clients (ages 18-59) are served annually throughout the system. Based on DMH statistical data for fiscal year 1998, during which this study was conducted, 1,034 patients who were 18-54 years of age and diagnosed with schizophrenia or schizoaffective disorder were admitted to the two acute psychiatric facilities; 66.4 percent were nonwhite (predominantly African-American), and 61 percent were male, with an average age of 38 years. Patients in this group had an average of 32 days of hospitalization during fiscal year 1998 and an average of eight lifetime hospitalizations. Both hospitals are accredited by the Joint Commission on Accreditation of Healthcare Organizations (JCAHO) and adhere to those standards of care. For these patients, there is a wide range of local services available, including Program for Assertive Community Treatment (PACT)-model intensive case management teams, day rehabilitative services, and dual disorders treatment, as well as regular outpatient, office-based service. In the regular outpatient system, caseloads tend to be high (80-100 patients) for clinical case managers as well as psychiatrists and nursing staff. All of the mental health centers are accredited as Rehabilitation Accreditation Commission (CARF) or by JCAHO and maintain quality controls for clinical, psychosocial, and pharmacotherapy services and medical records according to applicable standards of practice.
Subjects. At study entry, patients who were between the ages of 18 and 54, who had a primary diagnosis of schizophrenia or schizoaffective disorder using DSM-1V (American Psychiatric Association 1994) criteria, were screened for eligibility during inpatient stays at the two state acute care psychiatric hospitals between October 1997 and November 1998. Inclusion criteria also included having two or more acute psychiatric hospitalizations within the prior 12 months, being noncompliant with outpatient treatment, and not taking a novel antipsychotic medication for 6 to 8 weeks or more during the 3 months prior to the index hospitalization. Exclusion criteria were having a DSM-FV primary diagnosis of organic brain syndrome, mental retardation, or a substance-related disorder, as determined by the treating psychiatrist either in the index hospitalizations or in maintenance treatment.
Patients, their treating physicians, or both were asked to participate in the study in an assigned medication group to comply with Institutional Review Board requirements and the clinical standards of the two hospitals (i.e., a patient receiving an antipsychotic medication must be told what is being prescribed, why it is being prescribed, and what its side effect profile is). Research staff explained the nature of the research study-that is, the random assignment to a medication and the study procedures-while clinical staff explained the possible side effects of the medication. Treating physicians were able to refuse participation on behalf of patients for medical reasons, and patients themselves could also refuse to participate. All study patients provided written, informed consent to participate in the research as well as consent to be treated with the assigned/prescribed antipsychotic medication. Research participation included the 3 months prior to the index hospitalization and randomization, so that existing data from secondary sources (medical records and the DMH management information system) could be compiled for the baseline period.
Procedures.
A 12-month, prospective, open-label RCT design was employed to investigate clinical and cost outcomes across multiple dimensions. Eligible patients were randomly assigned to receive one of two types of novel antipsychotic medications (risperidone and olanzapine) or to continue to receive the conventional antipsychotic medication they were already prescribed, predominantly haloperidol. An adaptive randomization procedure was used (Wei and Lachin 1988) , which balanced their assignment to a treatment group on six related variables: patient demographics (age, gender, ethnicity), diagnosis (schizophrenia vs. schizoaffective disorder), number of hospitalizations in lifetime, and number of days in the hospital in the preceding 6 months. Because randomization occurred before the baseline assessment of positive and negative symptoms was performed, "number of lifetime" and "total number of days of acute hospitalization in the prior 6 months" were used as proxies for severity/chronicity or acuity in the randomization procedure. In practice, the sequential, adaptive randomization program compensates for patients who refuse to participate by assigning a patient who has similar characteristics to the group in which the refusal occurred. During subsequent hospitalizations, if the patient who originally refused to participate then consented, he or she entered the originally assigned medication group; thus, no crossover in randomized medication groups occurred.
Patients were then interviewed (i.e., asked to recall their symptoms and functioning during the 3 months prior to the interview) at baseline and at 3-month intervals for up to 12 months after randomization. All four interviewers were master's-level staff who had previous clinical experience working with schizophrenia patients but had no clinical contact with the subjects during this study. During the first 72 hours after index hospital admission, while potential subjects were being screened and randomized, acute symptoms were stabilized using short-acting, oral conventional antipsychotic medications. After entering the study, titration and maintenance dosing of the assigned medication was not constrained by the study protocol, except that the assigned medication was expected to be used to the extent possible; rather, dosing was determined by the patient's treating physician according to manufacturer recommendations. Use and dosage of supplemental conventional antipsychotic medications and of augmenting moodstabilizing medications or anticholinergic medications was left to the discretion of the treating physician.
Following discharge from the index hospitalization, patients were treated at the local mental health centers by psychiatrists who were allowed to change the maintenance medication regimen based on patient presentation, but these changes were closely monitored through medical chart reviews. The four trained research interviewers were not blind to the group assignment, but they generally did not know what medication regimen the patient was actually receiving until the medical record was reviewed following each interview. In practice, the clinicians and research interviewers had large caseloads, and study subjects were dispersed across 17 mental health centers, numerous treating psychiatrists, and numerous case managers so that being enrolled in the study most likely did not alter usual service delivery for these patients.
Outcome Measures. Standard outcome instruments employed in this study were the PANSS (Kay et al. 1987 ), the Brief Psychiatric Rating Scale (BPRS,_ 7 scoring derived from the PANSS; Overall and Gorham 1962) , the
Diagnostic Interview Schedule III-R (D1S-III-R)
Depression and Mania Modules (Blouin 1991) , the Role Functioning Scale (RFS; Wieduwilt and Jerrell 1998) , the Social Adjustment Scale-Severely Mentally 111 (Wieduwilt and Jerrell 1999) , the Dyskinesia Identification System Condensed User Scale (DISCUS; Kalachnik and Sprague 1994) , the Simpson-Angus Extrapyramidal Symptoms Scale (S-A EPS; Simpson and Angus 1970) , the Barnes Akathisia Scale (Barnes 1989) , the Chemical Use, Abuse, and Dependence Scale (CUAD; McGovern and Morrison 1992; Appleby et al. 1996) , and the Client Satisfaction Questionnaire-8 (CSQ-8; Attkisson and Greenfield 1995) . To achieve an acceptable level of interrater reliability among the four research interviewers (about 0.92), all interviewers received specialized training in performing the PANSS and side effects ratings, had training and experience in previous clinical trials using the other psychosocial functioning and DIS instruments, and had experience in maintaining interrater reliability (Jerrell 1999) .
Indicators of pharmacotherapy practice and patient compliance, extracted from medical record reviews for each patient for each time period, entailed whether the patient was prescribed the assigned medications, compliant with the prescribed medications (i.e., getting regular injections, taking oral medications as prescribed, getting refills on time, etc.), prescribed supplemental antipsychotic medications (i.e., both a novel and a conventional medication), prescribed an anticholinergic medication, or prescribed a mood stabilizer.
Service utilization, including rehospitalization, and costs were measured using three data sources. First, dates of each hospital admission and discharge were compiled for public and private facilities. The number of days the patient was hospitalized in the state mental health system for each time period of the study was tallied and multiplied by the average daily cost of providing care at the state facility where the episode occurred. Because Medicaid was the only third-party payment source for these patients, Medicaid payments for local emergency room visits (prior to admission) and hospitalization days in local private facilities were compiled for the same time periods of the study. Second, the outpatient services utilized by each patient were tallied from the state DMH data base. The average unit cost of providing each service at each mental health center (as calculated by the state DMH annually) was multiplied by the number of visits or hours of local mental health center service provided and summed for baseline and for each followup time period. Finally, costs of medications (antipsychotics, mood stabilizers, and anticholinergics) were estimated directly from the prescriptions in the medical record on a per dose basis, using per dose costs for the state DMH. Daily dosage costs were tallied for each medication and then multiplied by the length of time during each 3-month interval that the subject was prescribed each medication. Prescriptions were weighted by the level of patient compliance for more accurate estimation of costs; that is, if the patient was not coming in for an injection or a prescription for oral medication, no cost was tallied for that time period. Because all patients had funding for their medications from Medicaid, through DMH, or through the special legislative appropriation for this study, none of these patients received free or indigent care medications that eluded estimation. The public mental health and Medicaid data systems from which these data elements were extracted are routinely compiled, cleaned, and analyzed for special and annual reports, thus improving their accuracy and reliability. Data Analyses. Data for this study were analyzed using the PROC MIXED facility in SAS version 8.01e for repeated-measures designs. Given the longitudinal nature of the design, the inherent correlation of repeated assessments, and the presence of missing data across measurement occasions, PROC MIXED was deemed most appropriate for these analyses because it accommodates both randomly missing observations and subjects measured at different time points and estimates random subject-specific effects. The random regression analysis for each outcome variable was performed examining group X time interaction, but main effects for time are also reported below.
Covariates for these analyses were modeled as either time varying (e.g., anticholinergic medication use) or time invariant (e.g., gender and race). Preliminary analyses were conducted for each outcome to assess and select the best covariance structure for each analysis. All outcome estimates were computed via a restricted likelihood method. Six time-invariant covariates related to sociodemographic (gender, race, age 18-36 years at study intake), diagnostic (diagnosis of schizoaffective disorder), and baseline chronicity/severity (over seven previous psychiatric inpatient admissions, or more than four psychiatric inpatient days in the past 6 months) were examined for their ability to significantly contribute to each model. Only those covariates that significantly (p = 0.05) contributed to each model were subsequently included in each final model. One time-dependent covariate (anticholinergic medication use) was included in all models that assessed medication side effects. All multiple-comparison analyses employed the Tukey-Kramer adjustment to protect the overall 0.05 significance level. Plots for the least squares means estimates by occasion and medication group are presented for each significant outcome, controlling for appropriate covariates where applicable.
Time to index hospitalization discharge and initial rehospitalization were assessed using Kaplan-Meier survival analysis and Cox proportional hazards model regression. Multiple logistic regression analyses using indicator variables for treatment group and time period were conducted to determine the relative odds associated with changes in medication compliance, taking assigned antipsychotic medications, and using supplemental medications, side effect medications, and mood stabilizers after controlling for treatment group and followup time period. In these logistic regressions, the first 3-month time period after randomization was used as the referent category for time indicators and the conventional medication group as the referent category for treatment group indicators. All outcomes were analyzed according to an "intentto-treat" framework in which the medication group to which the person was initially assigned served as the main comparison group.
Results
Baseline Description. A total sample of 343 patients who met inclusion criteria were screened and randomly assigned to the study groups. Of those assigned, 74 patients (21.6%) refused to participate, and a physician refused on behalf of 146 patients (42.5%). In 70 of these cases, physicians placed the patient on a medication other than the one assigned or did not want to change the prescribed regimen (predominantly haloperidol); in 76 cases, physicians refused because of patient-related concernsfor instance, too noncompliant, too violent, or too substance abusing (but no current primary substance-related disorder was documented) to be on an oral medication. Fifteen patients went into a clozapine study group and were not included with this analysis.
The final study sample of 108 patients was as follows: 63 percent were male; 73 percent were nonwhite (predominantly African-American); and 67 percent were diagnosed with schizophrenia (vs. schizoaffective disorder). The average age of these patients was 37 years. On average, patients had 13 days of acute hospitalization in the 6 months prior to participating in this study and an average often lifetime hospitalizations (table 1) .
To assess the extent of bias that these refusals might cause in the final sample, those who refused and those who consented were compared on all the variables used to balance the randomized sample, with no statistically significant differences (table 2). Differential refusal rates across the three medication groups were not statistically significant either: 73.7 percent for the olanzapine group, 69.5 percent for the risperidone group, and 62.2 percent for the conventional group (x 2 = 3.54, p = 0.17). The only statistically significant difference found between patients in the three medication groups on any of the variables used to balance the sample (table 1) or in their average grouped data at baseline for any of the 15 outcomes to be presented was for mean number of 24-hour care days in the preceding 6 months. The olanzapine group had significantly more acute hospital days in the 6 months prior to entering the study than either the risperidone group or the conventional medication group.
During the 3 months prior to randomization into this study, the pharmacotherapeutic history of patients in each assigned medication group may be described as follows (table 1) . Of the 30 patients assigned to the olanzapine group, 7 patients had previously taken olanzapine (mean of 30 days, average daily dose of 12 mg) and 3 patients had previously taken risperidone (mean of 46 days, at 5 mg). The 36 patients assigned to the risperidone group included 1 patient who had previously taken olanzapine (mean of 26 days, at 20 mg) and 14 patients who had previously taken risperidone (mean of 39 days, at 4 mg). The 29 patients assigned to the conventional group included 4 patients who had previously taken olanzapine (mean of 62 days, at 12 mg) and 5 patients who had previously taken risperidone (mean of 34 days, at 4 mg); all 4 patients who had previously taken olanzapine were among the 5 who had previously taken risperidone. For some subjects, previous exposure exceeded the established inclusion criteria, but this discrepancy between local clinician and hospital clinician communication, and the medical record documentation, was not apparent until months after the trial began, so it is noted/quantified here but the subjects were not dropped from the study or this analysis.
Descriptive data regarding baseline differences in compliance with prescribed treatment, supplemental antipsychotic medications (combined novel and conventional medications), EPS medications, and mood stabilizers are also presented in table 1. Chi-square tests indicated that the only significant difference between the three groups at baseline in pharmacotherapy practices and patient adherence was for the baseline use of atypical medications (x 2 = 11.09, p = 0.004). Multiple comparison analyses across the three medication groups revealed that the conventional medication group was significantly less likely to have been prescribed a novel antipsychotic medication at baseline compared with those in the risperidone group (x 2= 10.82, p = 0.001) and the olanzapine group (x 2 = 6.33, p = 0.01).
Treatments Received. While the treatments examined were not constrained by study procedures, they were closely monitored. Descriptive data regarding the average daily doses over time per medication group, as well as percentages of patients prescribed the assigned medication, compliant with the prescribed medication, prescribed supplemental antipsychotic medication (both novel and conventional), prescribed EPS medication, and prescribed a mood stabilizer are presented in O marized briefly. In the olanzapine group, the average daily dose ranged from 12 to 15 mg, and the average number of days the medication was taken ranged from 60 days at 3-month followup to 83 days at 12-month followup. In the risperidone group, the average daily dose ranged from 4 to 6 mg, and the average number of days the medication was taken ranged from 57 days at 3-month followup to 72 days at 9-month followup. In the conventional group, the average daily dose of oral haloperidol ranged from 14 to 17 mg, or a monthly average dose of haloperidol decanoate ranged from 210 mg at 3-month followup to 150 mg at 12-month followup, and the average number of days the medication was taken ranged from 50 days at 3-month followup to 77 days at 12-month followup. For those in the conventional group who were prescribed fluphenazine, the average dose of fluphenazine decanoate remained consistent at 37.5 mg every 2 weeks across all followup periods, and the average number of days the medication was taken ranged from 55 days at 3-month followup to 50 days at 12-month followup. At 12-month followup across the medication groups, 59 to 72 percent of patients in the study were still being prescribed the assigned medication by their treating psychiatrist, and patient compliance rates ranged from 69 percent to 96 percent. There was a high percentage of patients in all groups prescribed anticholinergic medications (44%-60% over time) and mood stabilizers (59%-72% over time) in the novel medication groups.
Supplemental conventional medications were provided to patients in both the olanzapine and the risperidone groups during the 12 months of study treatment. The most common patterns of supplementation, for a variable number of patients at varying dosages and varying number of days prescribed, may be summarized as follows. In the olanzapine group only two to three patients received supplemental oral or depot fluphenazine. The olanzapine group included four patients who received oral haloperidol an increasing average number of days over time (51-71 days) at a decreasing average daily dose over time of 17 to 15.5 mg, and six to eight patients who received haloperidol decanoate at an increasing average number of days over time (50-70 days) at an average monthly dose of 120 to 150 mg. Likewise, in the risperidone group, only two to three patients received supplemental oral or depot fluphenazine, whereas five to nine patients received oral haloperidol an increasing average number of days over time (28-75 days) at an average daily dose of between 11 and 14 mg, and 10-12 patients received haloperidol decanoate at an increasing average number of days over time (57-72 days) at an average monthly dose over time of 150 to 180mg.
Results of the logistic regression analyses comparing these pharmacotherapy variables indicated that the odds of Furthermore, the odds of being prescribed supplemental antipsychotic medications (i.e., both a novel and a conventional) were almost three times higher for the olanzapine group (Wald Table 4 presents the means, standard deviations, and number of cases for all outcome measures over time examined in the regression analyses.
Symptomatology. PANSS positive symptoms indicated no significant time X group interaction (F = 1.11;/? = 0.35), after controlling for the effects of gender and psychiatric chronicity (more than seven lifetime psychiatric inpatient admissions), but symptoms reported decreased significantly over time, between baseline and 12 months (r = 5.15, p < 0.0001). PANSS negative symptoms indicated no significant time X group interaction (F = 0.90; p = 0.55), but a significant time effect was evident (F = 4.37; p = 0.0004), with decreases in symptoms between baseline and 9-month followup it = 4.08, p = 0.001). Similarly, the BPRS,_ 7 total score indicated a significant time effect only (F = 15.40; p < 0.0001), with significant decreases in BPRS scores between baseline and 12 months (r = 5.90, p < 0.0001). 
DIS-III-R Depression symptoms and DIS-III-R
Mania symptoms showed significant increases over time between baseline and 12 months (F = 11.30; p = 0.000) but no differential medication group effects. The DIS-III-R Depression and Mania regression analyses were also performed, controlling for taking "prescribed antidepressant medication" or "prescribed mood stabilizer," but the results were unchanged on either outcome. CUAD substance abuse symptoms indicated a significant time effect only (F = 2.76; p = 0.01), with decreases in substance abuse symptoms between baseline reports and those at 3 months (t = 3.36, p = 0.02).
Rated psychosocial functioning as measured by the RFS analyses indicated no significant time X group interaction (F = 1.04; p = 0.42), after controlling for the effects of psychiatric chronicity, but role functioning increased over time (F = 7.92; p = 0.0001), between baseline and 12 months (t -4.29, p = 0.0006). Self-reported psychosocial functioning indicated no significant interaction effect (F = 1.39; p = 0.17), after controlling for the effects of number of psychiatric hospitalizations.
Side effects. DISCUS side effects indicated a significant effect for time only (F = 5.11; p < 0.0001), after controlling for the time-dependent effects of anticholinergic medication use, with decreasing numbers of side effects noted between baseline and 12 months (/ = 4.24, p -0.0007). S-A EPS also indicated a significant effect for time only (F = 9.43; p < 0.0001), after controlling for the time-dependent effects of anticholinergic medication use, with significant decreases between baseline and 12 months (r = 6.55, p < 0.0001). Global Barnes Akathisia Scale ratings indicated a significant effect for time only (F = 3.23; p = 0.005), after controlling for the time-dependent effects of anticholinergic medication use, with significant decreases in ratings between baseline and 12 months (t = 3.99, p = 0.002).
Time to discharge from index hospitalization. The overall log rank test for equality of Kaplan-Meier survival distributions indicated that there was no significant difference between the three groups at the a = 0.05 level with respect to either the overall log rank test for equality of survival distributions (x 2 = 0.83, df = 2, p = 0.66) or in any of the pairwise comparisons between groups. Results from the overall Cox proportional hazard regression model showed no significant differences in time to index discharge between the three groups (x 2 = 0.52, df=2,p = 0.77).
Time to initial rehospitalizatJon. Three of the 108 subjects in the final sample were dropped in conducting this survival analysis because they were never released from the hospital during the 12-month followup period. The overall log rank test for equality of Kaplan-Meier sur- Note.-BAS = Barnes Akathisia Scale; BPRS = Brief Psychiatric Rating Scale; CSQ-8 = Client Satisfaction Questionnaire-8; CUAD = Chemical Use, Abuse, and Dependence Scale; DIS = Diagnostic Interivew Schedule; DISCUS = Dyskinesla Identification System Condensed User Scale; S-A EPS = Simpson-Angus Extrapyramidai Symptoms Scale; MH = mental health; PANSS = Positive and Negative Syndrome Scale; RFS = Role Functioning Scale; SAS-SMI = Social Adjustment Scale-Severely Mentally III; SD = standard deviation.
| vival distributions indicated no significant difference between the three groups in their survival distributions at the a = 0.05 level (x 2 = 2.60, df=2,p = 0.27). Results from the final Cox proportional hazard regression model showed no significant difference in the relative risk of rehospitalization between the three groups (x 2 = 2.59, df= 2,p = 0.27).
Costs of treatment Inpatient mental health service costs (using log transformations) indicated no differential effect in medication groups, but a significant time effect (F = 67.48; p < 0.0001) was evident, with a decrease between baseline and 12-month followup (t = 10.19, p < 0.0001). Outpatient mental health service costs (using log transformations) also indicated significant effects for time only (F = 4.75; p = 0.001), with a significant decrease between baseline and 12-month followup (f = 3.81, p = 0.002).
Psychiatric medication cost results (a combination of all psychiatric medication costs, not just the assigned antipsychotic medication cost) indicated a significant medication group X time interaction (F = 6.33, p < 0.0001) (figure 4). Multiple comparisons across medication groups revealed that both the olanzapine group (t = 2.84, p = 0.02) and the risperidone group (t = 3.17, p = 0.005) had significantly higher total mental health treatment costs on average over the course of the study as compared with the conventional group. Total mental health treatment costs (using log transformations of inpatient, outpatient, and psychiatric medication costs) changed significantly over time (F = 18.19; p = 0.0001) , increasing between baseline and 3-month followup (/ = 4.45, p = 0.0001), which reflects the index hospitalization, but then significantly decreasing between the 3-month and the 12-month followup (f = 3.54, p = 0.004).
Client satisfaction. Client satisfaction with services indicated a significant effect for time only (F = 7.92; p < 0.0001), after controlling for the effects of psychiatric chronicity, with increases in satisfaction between baseline and 3-month followup (t = 3.12, p = 0.03).
Discussion
The major findings of this study can be summarized as follows. Compliance in taking the assigned medication was significantly higher in the olanzapine group compared with the conventional group during the study. There were other important pharmacotherapy changes over time-that is, in being prescribed the assigned medication (dropped off between 6 and 12 months followup), in compliance with taking the prescribed medication and in being prescribed anticholinergic medication (dropped off at 12 months), and important medication group differences in being prescribed supplemental medications and mood stabilizers (3-4 times higher in both novel groups).
No medication group differences in the symptoms of schizophrenia, side effects, psychosocial functioning, time to discharge for index hospitalization, survival to initial rehospitalization, or client satisfaction with services were evident in this sample. Over time, across medication groups, symptoms of schizophrenia were decreasing; whereas affective symptoms were increasing, side effects were decreasing, rated psychosocial functioning was increasing, and total mental health service costs were decreasing. Psychiatric medication costs were increasing more over time in the olanzapine group, and, to a lesser extent, in the risperidone group, compared with the conventional group. However, these medication costs reflect not only the cost of the novel medications but also the extensive use of supplementing, augmenting, and anticholinergic medications in the novel groups. These results expand our knowledge base in many ways. They differ from previous findings regarding the efficacy of the novel medications in reducing the positive and negative symptoms of schizophrenia (Marder and Meibach 1994; Peuskens 1995; Beasley et al. 1996a Beasley et al. , 19966, 1997 Tollefson et al. 1997; Tran et al. 1997; Ho et al. 1999; Leucht et al. 1999; Conley and Mahmoud 2001) and in the percentage of patients in the novel groups reporting EPS or taking anticholinergic medications Jibson and Tandon 1998; Ho et al. 1999; Leucht et al. 1999; Conley and Mahmoud 2001) . One major difference between this study and previous studies is that no subject was omitted from the sample for being a "nonresponder"; hence, the "modest" efficacy differences between novel and conventional medications evident in previous studies might not be evident. Furthermore, because this study focused on patients receiving "usual practice," the extent of supplementation and use of anticholinergic medications to ensure that symptoms and side effects were controlled prior to and following discharge might obfuscate efficacy differences between the novel and the conventional medications. Compliance rates were consistently higher than baseline until the 12-month followup, which is especially noteworthy in a patient population distinguished by high rates of noncompliance and by pharmacotherapy practice, which is frequently driven by noncompliance.
Mood symptoms in this sample were increasing over time, unlike results from previous investigations Conley and Mahmoud 2001) . Augmentation of pharmacotherapy using mood stabilizers was higher (56%-72% in the novel groups) than would be expected based on the percentage of patients diagnosed with schizoaffective disorder across medication groups (33%) or those reporting depression (20%) or mania (20%) symptoms or akathisia (15%-25%). The reasons for these discrepancies are unclear: previous clinical reports suggest these novel antipsychotics trigger or exacerbate mania, akathisia, or agitation symptoms (Dwight et al. 1994; Sanders and Mossman 1999) ; other reports indicate that African-Americans (77% of this study sample) have high levels of undiagnosed affective components to their psychotic symptoms (Chen et al. 1996) , or clinicians may overmanage patients whose psychotic symptoms clear enough or resolve to the point to be more assertive in their treatment. Rehospitalization rates in this sample were consistent with those of previous studies over 12 months (45%-66%) (Ayuso-Gutierrez and Ma del Rio Vega 1997; DeQuardo and Tandon 1998; Hogarty and Ulrich 1998).
The utility of these results, however, needs to be judged in light of the strengths and limitations of the study design and methods. Effectiveness studies evaluate treatment effects on multiple health outcomes under usual care conditions (Wells 1999) . In this study, RCT methods were applied in community treatment settings with a representative acute care sample, using standard instruments and longer followup periods, to balance and maximize both internal and external validity. Several important correlates of outcome (e.g., noncompliance, supplementation, and use of anticholinergic or thymoleptic medications) were monitored and used in the regression analyses as covariates to control for their influence. However, methodological compromises included no double-blind conditions and much less treatment standardization than is usual in an efficacy study. Because variance may be great, especially for cost data, the study's small sample size (primarily because of limited clinician cooperation in the recruitment phase) decreased the statistical power available for detecting medication group X time interactions on most outcomes and prevented me from examining differences in outcome across the 17 mental health centers participating in the study.
Potential biases due to differential refusal rates and selection factors were analyzed; however, there are probably other unmeasured sources of bias as well, such as the influence of the treating clinicians on the final patient outcomes, the influence on participation of knowing which medication group patients had been randomized to before informed consent was obtained, or the degree to which those assigned to the risperidone or olanzapine groups were more "treatment resistant" because a higher percentage of them had received treatment with a novel medication prior to participation in this study. For example, the olanzapine group had significantly more acute inpatient days in the 6 months prior to entry into the study, which could reflect more acuity/severity in their symptoms, more instability in their functioning, more noncompliance with their prescribed medication regimens, or more reluctance to be in the study on a new medication. Triangulating information about the refusal rate being highest for those assigned to the olanzapine group, and the mean number of prior acute hospitalization days being highest for the olanzapine group, there could have been reluctance among patients to participate in the olanzapine group. This reluctance might be reflected in their slightly lower baseline PANSS symptoms, because they received more days of inpatient service and oral haloperidol treatment prior to agreeing to participate and taking the assigned medication.
Overall, the study design aimed for breadth of outcomes rather than depth of clinical detail and strove to maximize generalizability by using a representative acute care sample, inclusion/exclusion criteria that reflect the diversity of patients in public mental health settings, and a sample generally reflective both of prior efficacy studies in terms of diagnosis, age, gender, and prior hospitalizations (Marder and Meibach 1994; Tollefson et al. 1997; Tunis et al. 1999 ) and of the patients most likely to use acute public mental health services-that is, nonwhite males (Hu and Jerrell 1991; Chen et al. 1996) . These results need to be replicated in larger clinical trial samples, conducted in usual care settings, under more rigorous "bunded" conditions to draw definitive conclusions, and the issues underpinning the clinical practices encountered and their subsequent outcomes need to be explored further.
Conclusions
This study sheds some additional light on the effectiveness and costs of using olanzapine, risperidone, or conventional antipsychotic medications in patients from a large, public mental health system receiving multiple episodes of acute care. Although their costs were greater overall, the olanzapine group demonstrated better compliance over time. These results underscore the need to monitor a broad range of outcomes over an extended period of time, in order to determine changes in costs and effectiveness measures that might be expected in usual practice settings. However, further research is needed in usual practice settings, employing more rigorous research designs with larger samples to draw more specific conclusions about the comparative costs and effectiveness of these medications.
